GlassScriptPhysician profile
Christopher J Salud
NPI 1669703492
$1,224.26
in general payments reported to CMS, 2019-2025
14 companies · $36.20 in 2025
The $36.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $474 · 2021: $24.07 · 2022: $45.37 · 2023: $14.41 · 2025: $36.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $475.25 | 2019-2020 | |
| Novo Nordisk INC | $343.24 | 2019-2023 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $89.52 | 2020 | |
| Allergan, INC. | $68.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.48 | 2019 | |
| Amgen INC. | $37.50 | 2019 | |
| Exact Sciences Corporation | $36.20 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $35.56 | 2020 | |
| Merck Sharp & Dohme LLC | $25.68 | 2019 | |
| Fidia Pharma USA INC. | $14.77 | 2022 | |
| Glaxosmithkline, LLC. | $14.59 | 2022 | |
| Phadia US INC. | $11.76 | 2019 | |
| Lilly USA, LLC | $11.76 | 2019 | |
| Horizon Therapeutics Plc | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Salud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.